Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206231 | 1.00 | ALDH1A1 (0.72) | ALDH1A1HPGDL3MBTL1KMT2ANPC1 | |
| SCHEMBL4167189 | 0.92 | ALDH1A1 (0.84) | ALDH1A1HPGDKMT2ANPC1KDM4E | |
| SCHEMBL14934861 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HPGDKMT2ANPC1KDM4E | |
| SCHEMBL8062381 | 0.84 | ALDH1A1 (1.00) | ALDH1A1HPGDL3MBTL1NPC1KDM4E | |
| SCHEMBL1844542 | 0.81 | ALDH1A1 (0.72) | ALDH1A1HPGDKMT2ANPC1KDM4E | |
| SCHEMBL28404651 | 0.81 | ALDH1A1 (0.72) | ALDH1A1HPGDL3MBTL1KMT2ANPC1 | |
| SCHEMBL28407968 | 0.80 | ALDH1A1 (0.65) | ALDH1A1HPGDKMT2ANPC1KDM4E | |
| SCHEMBL28414245 | 0.80 | ALDH1A1 (0.65) | ALDH1A1HPGDKMT2ANPC1KDM4E | |
| SCHEMBL10515142 | 0.79 | ALDH1A1 (0.63) | ALDH1A1HPGDL3MBTL1KMT2ANPC1 | |
| SCHEMBL28409708 | 0.79 | ALDH1A1 (0.63) | ALDH1A1HPGDKMT2ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1595871-A2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2005-11-16 | — | — | EP | disclosed |